Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/advs.202103266 http://scihub22266oqcxt.onion/10.1002/advs.202103266 34687279!8646611!34687279     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34687279&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Sci+(Weinh) 2021 ; 8 (23): e2103266 Nephropedia Template TP {{tp|p=34687279|t=2021. Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis |pdf=|usr=}}{{34687279}} gab.com Text Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis JO: Adv Sci (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=34687279 #FOAvip Activation of endothelial cells following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be the primary driver for the increasingly recognized thrombotic complications in coronavirus disease 2019 patients, potentially due to the SARS-CoV-2 Spike protein binding to the human angiotensin-converting enzyme 2 (hACE2). Vaccination therapies use the same Spike sequence or protein to boost host immune response as a protective mechanism against SARS-CoV-2 infection. As a result, cases of thrombotic events are reported following vaccination. Although vaccines are generally considered safe, due to genetic heterogeneity, age, or the presence of comorbidities in the population worldwide, the prediction of severe adverse outcome in patients remains a challenge. To elucidate Spike proteins underlying patient-specific-vascular thrombosis, the human microcirculation environment is recapitulated using a novel microfluidic platform coated with human endothelial cells and exposed to patient specific whole blood. Here, the blood coagulation effect is tested after exposure to Spike protein in nanoparticles and Spike variant D614G in viral vectors and the results are corroborated using live SARS-CoV-2. Of note, two potential strategies are also examined to reduce blood clot formation, by using nanoliposome-hACE2 and anti-Interleukin (IL) 6 antibodies. Twit Text FOAVip Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis ????Adv Sci (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=34687279 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34687279 #FOAvip English Wikipedia <ref>{{Cite pmid|34687279}}</ref> Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis #MMPMID34687279 Satta S; Lai A; Cavallero S; Williamson C; Chen J; Blazquez-Medela AM; Roustaei M; Dillon BJ; Ashammakhi N; Carlo DD; Li Z; Sun R; Hsiai TK Adv Sci (Weinh) 2021[Dec]; 8 (23): e2103266 PMID34687279show ga Activation of endothelial cells following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be the primary driver for the increasingly recognized thrombotic complications in coronavirus disease 2019 patients, potentially due to the SARS-CoV-2 Spike protein binding to the human angiotensin-converting enzyme 2 (hACE2). Vaccination therapies use the same Spike sequence or protein to boost host immune response as a protective mechanism against SARS-CoV-2 infection. As a result, cases of thrombotic events are reported following vaccination. Although vaccines are generally considered safe, due to genetic heterogeneity, age, or the presence of comorbidities in the population worldwide, the prediction of severe adverse outcome in patients remains a challenge. To elucidate Spike proteins underlying patient-specific-vascular thrombosis, the human microcirculation environment is recapitulated using a novel microfluidic platform coated with human endothelial cells and exposed to patient specific whole blood. Here, the blood coagulation effect is tested after exposure to Spike protein in nanoparticles and Spike variant D614G in viral vectors and the results are corroborated using live SARS-CoV-2. Of note, two potential strategies are also examined to reduce blood clot formation, by using nanoliposome-hACE2 and anti-Interleukin (IL) 6 antibodies. |Angiotensin-Converting Enzyme 2/chemistry/genetics/metabolism[MESH] |Antibodies/chemistry/immunology/metabolism[MESH] |Blood Coagulation/*physiology[MESH] |COVID-19/diagnosis/virology[MESH] |Endothelial Cells/chemistry/cytology/metabolism[MESH] |Fibrin/chemistry/metabolism[MESH] |Genetic Vectors/genetics/metabolism[MESH] |Humans[MESH] |Interleukin-6/immunology[MESH] |Liposomes/chemistry[MESH] |Microfluidics/methods[MESH] |Mutation[MESH] |Nanoparticles/chemistry[MESH] |Platelet Aggregation[MESH] |SARS-CoV-2/*isolation & purification/metabolism[MESH]Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated (epmc).pdf DeepDyve Pubget Overpricing